
In Vivo Proof of Concept and Target Identification Using Small Molecule Stimulators of Brown AdipogenesisAward last edited on: 5/21/2023
Sponsored Program
SBIRAwarding Agency
NIH : NIDDKTotal Award Amount
$2,283,948Award Phase
2Solicitation Topic Code
847Principal Investigator
Olivier BossCompany Information
Energesis Pharmaceuticals Inc
One Kendall Square Building 200 Suite 2203
Cambridge, MA 02139
Cambridge, MA 02139
(617) 437-0881 |
info@energesispharma.com |
www.energesispharma.com |
Location: Single
Congr. District: 07
County: Middlesex
Congr. District: 07
County: Middlesex
Phase I
Contract Number: 1R43DK125193-01A1Start Date: 7/1/2020 Completed: 6/30/2021
Phase I year
2020Phase I Amount
$295,420Public Health Relevance Statement:
PROJECT NARRATIVE Obesity has reached epidemic proportions in the U.S. and globally. While most weight loss agents rely on suppressing appetite to reduce caloric intake, increasing energy expenditure is another approach to weight control. Brown adipose tissue (BAT) is a recruitable, thermogenic tissue with the capacity to utilize large amounts of fat and glucose, and which is present in reduced amounts in obese patients. We discovered a human BAT progenitor/stem cell and have used this as a tool to discover a small molecule that potently recruits new BAT cells. Here we propose to generate and test novel analogs of this molecule with improved activity and physicochemical and ADME properties that would be suitable for a development candidate, with the aim of increasing brown fat and treating obesity in patients.
Project Terms:
absorption; Acids; Adipocytes; Adult; analog; Antidiabetic Drugs; Artificial Membranes; Arts; Atrophic; Award; base; Biological Assay; Biological Availability; Body Temperature; Body Weight decreased; Brown Fat; Cardiovascular Diseases; Cell Membrane Permeability; Cells; Chemistry; Collaborations; Data; design; Desire for food; Development; Diabetes Mellitus; Dose; drug candidate; Dyslipidemias; efficacy study; energy balance; Energy Intake; Energy Metabolism; Epidemic; Evaluation; experience; Fatty acid glycerol esters; flexibility; Generations; genomic locus; Glucose; Goals; Human; human data; improved; In Vitro; in vitro activity; in vitro Assay; in vitro Bioassay; in vivo; in vivo evaluation; Individual; insulin sensitivity; Investments; Lead; lead candidate; lead optimization; Libraries; Link; lipid biosynthesis; Lipolysis; Liver; Maintenance; Measures; Mediating; Medical; Metabolic; Metabolic Diseases; metabolic rate; Metabolism; Mitochondria; mitochondrial uncoupling protein; Natural Products; Non-Insulin-Dependent Diabetes Mellitus; Normal tissue morphology; novel; Obesity; obesity treatment; Oral; Parents; Patients; Performance; Permeability; Pharmaceutical Chemistry; Pharmaceutical Preparations; pharmacophore; Phase; Physiology; Play; preservation; Probability; progenitor; programs; Property; Proteins; Provider; Publishing; recruit; Resistance; Resources; response; Rodent; Rodent Model; Role; Safety; scaffold; screening; Series; Skeletal Muscle; small molecule; Solubility; stem cells; Structure; Structure-Activity Relationship; Temperature; Testing; Thermogenesis; Thinness; Time; Tissues; tool; Toxicology; Translational Research; Translations; uncoupling protein 1; Weight maintenance regimen; Weight-Loss Drugs; Work
Phase II
Contract Number: 2R44DK125193-02Start Date: 7/1/2020 Completed: 7/31/2023
Phase II year
2021(last award dollars: 2022)
Phase II Amount
$1,988,528Public Health Relevance Statement:
PROJECT NARRATIVE Obesity has reached epidemic proportions in the U.S. and globally. While most weight loss agents rely on suppressing appetite to reduce caloric intake, increasing energy expenditure is another approach to weight control. Brown adipose tissue (BAT) is a recruitable, thermogenic tissue with the capacity to utilize large amounts of fat and glucose, and which is present in reduced amounts in obese patients. We discovered a human BAT progenitor/stem cell and have used it as a tool to discover a series of small molecule compounds that potently recruit new BAT cells. Here we propose to evaluate these compounds for in vivo efficacy and characterize their molecular mechanism of action, with the aim of increasing brown fat and treating obesity in patients.
Project Terms: